Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SIX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.
Discovering and developing innovative therapeutics for CNS disorders
Media
Press Releases - 2009
Newron raises CHF 7.9m in a private placement to international institutional investors20/11/2009 | 
ENG
| 
GER
| |
Newron returns rights to HF0420 - Phase I compound reverts to inventors in exchange for future milestone and royalty payments14/10/2009 |
ENG
|
GER
| |
Ralfinamide uniquely shows analgesic effects in a Central Pain model (Data presented at EFIC)11/09/2009 |
ENG
|
GER
| |
Newron reports half-year results 200910/09/2009 |
ENG
|
GER
| |
Preclinical results of ralfinamide in a model of central pain to be presented at the European Federation of IASP Chapters (EFIC) 6th International Congress03/09/2009 |
ENG
|
GER
| |
First Phase III Clinical Trial results of Safinamide in Advanced Parkinson's disease to be presented at the Movement Disorder Society's 13th International Congress03/06/2009 |
ENG
|
GER
| |
Newron Reports Initiation of SETTLE, the Second Phase III Clinical Trial of Safinamide in Advanced Parkinson's Disease07/05/2009 |
ENG
|
GER
| |
Newron shareholders approve financial statements 200829/04/2009 |
ENG
|
GER
| |
Newron Pharmaceuticals reports 2008 results02/04/2009 |
ENG
|
GER
| |
Newron randomizes first patients in Phase IIb/III study of ralfinamide in patients with NLBP/"EMEA Agreement"31/03/2009 |
ENG
|
GER
| |
Safinamide Significantly Improved Motor Function in Patients with Ad-vanced Parkinson's Disease in a Phase III Pivotal Trial03/02/2009 |
ENG
|
GER
|